On October 31, 2024 Starpharma (ASX: SPL, OTCQX: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, reported its Quarterly Activities Report and Appendix 4C for the quarter ended 30 September 2024 (Q1 FY25) (Press release, Starpharma, OCT 31, 2024, View Source [SID1234649515]). Starpharma’s closing cash balance as at 30 September 2024 was $24.0 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma’s Chief Executive Officer, Cheryl Maley, commented:
"This quarter has been a very important period for advancing the core programs that we anticipate will deliver the greatest value using our unique, clinically validated dendrimer technology. Our team remains highly focused on delivering meaningful results through these programs. We are making significant progress in each of our three strategic priorities outlined in May: maximising DEP asset value, accelerating early asset development, and building long-term sustainability. We are closely monitoring all programs to ensure efficiency and optimal outcomes along with long-term value creation. We understand that some key results are highly anticipated, and we are working diligently to achieve these milestones in a timely manner. We look forward to sharing further updates and engaging with shareholders at the AGM in November."